Blockbuster dreams for Pfizer's CDK inhibitor
Explore this paper's citation graph
Summary
Clinical data seen recently with Pfizer’s leading small-molecule CDK4/6 inhibitor palbociclib (PD-0332991) has rekindled interest in the concept of blocking cell cycle progression to stop cancer cell growth.
- Type
- article
- Published
- 2013-03-01
- Cited by
- 50
- References
- 0
- Access
- Open access
- OpenAlex
- https://openalex.org/W23471056
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:12619291
Keywords
Geography
References
No references recorded for this paper.
Cited by
- A novel approach to the design of selective inhibitors for cell cycle cyclin dependent kinases
- Novel Therapeutic Strategies in Lung Cancer
- Characterization of molecular and cellular functions of the cyclin‐dependent kinase CDK9 using a novel specific inhibitor
- MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
- The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes
- Rb and FZR1/Cdh1 determine CDK4/6-cyclin D requirement in C. elegans and human cancer cells
- Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.
- Cellular senescence: from physiology to pathology
- 6-Cyclohexylmethoxy-5-(cyano-NNO-azoxy)pyrimidine-4-amine: a new scaffold endowed with potent CDK2 inhibitory activity.
- 7SK small nuclear RNA inhibits cancer cell proliferation through apoptosis induction
- A theoretical study of the structure and protonation of Palbociclib (PD 0332991)
- The other side of the coin: The tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND–CDK4/6–RB axis
- Pfizer's CDK4/6 inhibitor approved for advanced breast cancer
- The Molecular Balancing Act of p16INK4a in Cancer and Aging
- Chemogenetic Evaluation of the Mitotic Kinesin CENP-E Reveals a Critical Role in Triple-Negative Breast Cancer
- Targeting cyclin-dependent kinases in anti-neoplastic therapy.
- E2F Inhibition Synergizes with Paclitaxel in Lung Cancer Cell Lines
- Fluorescent biosensors for drug discovery new tools for old targets--screening for inhibitors of cyclin-dependent kinases.
- KSHV viral cyclin interferes with T-cell development and induces lymphoma through Cdk6 and Notch activation in vivo
- Development of highly potent and selective diaminothiazole inhibitors of cyclin-dependent kinases
Related papers
No related papers recorded.